100+ datasets found
  1. m

    COVID-19 reporting

    • mass.gov
    Updated Oct 21, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Executive Office of Health and Human Services (2022). COVID-19 reporting [Dataset]. https://www.mass.gov/info-details/covid-19-reporting
    Explore at:
    Dataset updated
    Oct 21, 2022
    Dataset provided by
    Department of Public Health
    Executive Office of Health and Human Services
    Area covered
    Massachusetts
    Description

    The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

  2. f

    Data_Sheet_1_Novel Highly Divergent SARS-CoV-2 Lineage With the Spike...

    • frontiersin.figshare.com
    pdf
    Updated May 30, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Katherine Laiton-Donato; Jose A. Usme-Ciro; Carlos Franco-Muñoz; Diego A. Álvarez-Díaz; Hector Alejandro Ruiz-Moreno; Jhonnatan Reales-González; Diego Andrés Prada; Sheryll Corchuelo; Maria T. Herrera-Sepúlveda; Julian Naizaque; Gerardo Santamaría; Magdalena Wiesner; Diana Marcela Walteros; Martha Lucia Ospina Martínez; Marcela Mercado-Reyes (2023). Data_Sheet_1_Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K.PDF [Dataset]. http://doi.org/10.3389/fmed.2021.697605.s001
    Explore at:
    pdfAvailable download formats
    Dataset updated
    May 30, 2023
    Dataset provided by
    Frontiers
    Authors
    Katherine Laiton-Donato; Jose A. Usme-Ciro; Carlos Franco-Muñoz; Diego A. Álvarez-Díaz; Hector Alejandro Ruiz-Moreno; Jhonnatan Reales-González; Diego Andrés Prada; Sheryll Corchuelo; Maria T. Herrera-Sepúlveda; Julian Naizaque; Gerardo Santamaría; Magdalena Wiesner; Diana Marcela Walteros; Martha Lucia Ospina Martínez; Marcela Mercado-Reyes
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    COVID-19 pandemics has led to genetic diversification of SARS-CoV-2 and the appearance of variants with potential impact in transmissibility and viral escape from acquired immunity. We report a new and highly divergent lineage containing 21 distinctive mutations (10 non-synonymous, eight synonymous, and three substitutions in non-coding regions). The amino acid changes L249S and E484K located at the CTD and RBD of the Spike protein could be of special interest due to their potential biological role in the virus-host relationship. Further studies are required for monitoring the epidemiologic impact of this new lineage.

  3. e

    Coronavirus spike (S) glycoprotein S2 subunit heptad repeat 2 (HR2) region...

    • ebi.ac.uk
    Updated Jun 24, 2021
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2021). Coronavirus spike (S) glycoprotein S2 subunit heptad repeat 2 (HR2) region profile [Dataset]. https://www.ebi.ac.uk/interpro/entry/profile/PS51924
    Explore at:
    Dataset updated
    Jun 24, 2021
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Coronaviruses (CoVs) [E1] are a diverse group of enveloped, plus-stranded RNAviruses that infect humans and many animal species, in which they can causerespiratory, enteric, hepatic, central nervous system and neurologicaldiseases of varying severity. A CoV contains four structural proteins,including spike (S), envelope (E), membrane (M), and nucleocapsid (N)proteins. Among them, the S protein, which is located on the envelope surfaceof the virion, functions to mediate receptor recognition and membrane fusionand is therefore a key factor determining the virus tropism for a specificspecies. This protein is composed of an N-terminal receptor-binding domain(S1) and a C-terminal trans-membrane fusion domain (S2) .The S2 subunit contains two 4-3 heptad repeats (HRs) of hydrophobic residues,HR1 and HR2, typical of coiled coils, separated by an ~170-aa-long interveningdomain. The S2 subunit is expected to present rearrangement of its HRs to forma stable 6-helix bundle fusion core .HR1 forms a 24-turn alpha-helix, while HR2 adopts a mixed conformation: thecentral part fold into a nine-turn alpha-helix, while the residues on eitherside of the helix adopt an extended conformation. The HR1 region forms a longtrimeric helical coiled-coil structure with peptides from the HR2 regionpacking in an oblique antiparallel manner on the grooves of the HR1 trimer ina mixed extended and helical conformation. Packing of thehelical parts of HR2 on the HR1 trimer grooves and formation of a six-helicalbundle plays an important role in the formation of a stable post-fusionstructure. In contrast to their extended helical conformations in the post-fusion state, the HR1 motifs within S2 form several shorter helices in theirpre-fusion state .The profiles we developed cover the entire CoV S2-HR1 -HR2 regions.

  4. I

    Data from: Omicron spike function and neutralizing activity elicited by a...

    • immport.org
    • data.niaid.nih.gov
    url
    Updated Mar 28, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2024). Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines [Dataset]. http://doi.org/10.21430/m3fjy3o5gg
    Explore at:
    urlAvailable download formats
    Dataset updated
    Mar 28, 2024
    License

    https://www.immport.org/agreementhttps://www.immport.org/agreement

    Description

    To assess spike mutation impact on ACE2 binding, fusogenicity, and neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus.

  5. Z

    Synthetic single particle cryo-EM dataset of the SARS-CoV-2 spike protein

    • data.niaid.nih.gov
    • zenodo.org
    Updated Jan 23, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dari Kimanius (2024). Synthetic single particle cryo-EM dataset of the SARS-CoV-2 spike protein [Dataset]. https://data.niaid.nih.gov/resources?id=zenodo_7182155
    Explore at:
    Dataset updated
    Jan 23, 2024
    Dataset authored and provided by
    Dari Kimanius
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    PDBs were generated using molecular dynamics. See DESRES_README.txt for more details on molecular dynamics simulation. PDBs were converted to volumetric data using EMAN2. The image stack contains 100 000 projection images each of the 10 states (see PDBs), at an SNR of 1/10 in the following order:

    state00 (closed) state01 (closed) state02 (closed) state10 (intermediate) state11 (intermediate) state12 (intermediate) state13 (intermediate) state20 (open) state21 (open) state22 (open)

    Projections were made using relion_project. White gaussian noise with standard deviation 1.0 CTF multiplied signal High signal-to-noise ratio Image size 96x96x96

    MRC-files used for the projections not included, but can be generated using the PDB files. Final RELION reconstruction resolution is 5.33334 Angstrom (Nyqvist is at 5.33334).

    Command line for RELION reconstruction: relion_refine_mpi --o refine3d/run --auto_refine --split_random_halves --i rot_trans_ctf_noise/stack.star --ref pdb2mrc/state21.mrc --ini_high 20 --dont_combine_weights_via_disc --preread_images --pool 30 --pad 2 --ctf --particle_diameter 130 --flatten_solvent --zero_mask --oversampling 1 --healpix_order 2 --auto_local_healpix_order 4 --offset_range 5 --offset_step 2 --low_resol_join_halves 40 --norm --scale --j 2 --gpu --fristiter_cc --grad

    This dataset is generated as a testbed for cryo-EM heterogeneity analysis.

  6. n

    Coronavirus (Covid-19) Data in the United States

    • nytimes.com
    • openicpsr.org
    • +2more
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    New York Times, Coronavirus (Covid-19) Data in the United States [Dataset]. https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html
    Explore at:
    Dataset provided by
    New York Times
    Description

    The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

    Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

    We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

    The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

  7. g

    Covid-19: Spike map of cases/district | gimi9.com

    • gimi9.com
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Covid-19: Spike map of cases/district | gimi9.com [Dataset]. https://gimi9.com/dataset/eu_f79bbb6f-a351-4ad7-bdd1-50f0410733d4/
    Explore at:
    License

    CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
    License information was derived automatically

    Description

    The map shows the 7-day incidence of confirmed cases of COVID-19 in the Austrian districts on a daily basis since the data were available (26 February 2020) and puts them in relation to the political targets.

  8. e

    Coronavirus spike glycoprotein S1, C-terminal

    • ebi.ac.uk
    Updated Jul 1, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2020). Coronavirus spike glycoprotein S1, C-terminal [Dataset]. https://www.ebi.ac.uk/interpro/entry/IPR043607
    Explore at:
    Dataset updated
    Jul 1, 2020
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    The coronavirus spike is an envelope glycoprotein which aids viral entry into the host cell. The precursor spike protein can be cleaved into three chains: spike protein S1, S2 and S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Spike protein S2 mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Spike protein S2' acts as a viral fusion peptide which is unmasked following S2 cleavage occurring upon virus endocytosis .S1 contains two major domains: an N-terminal domain (NTD) and a receptor-binding domain (S1 RBD) also referred to as the S1 CTD or domain B. Either the S1 NTD or S1 RBD, or occasionally both, are involved in binding the host receptors .

  9. I

    Evidence for retained spike-binding and neutralizing activity against...

    • immport.org
    • data.niaid.nih.gov
    url
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients [Dataset]. http://doi.org/10.21430/m35sd2inua
    Explore at:
    urlAvailable download formats
    License

    https://www.immport.org/agreementhttps://www.immport.org/agreement

    Description

    To evaluate the neutralization and binding activities of sera collected from COVID-19 mRNA vaccine recipients against current SARS-CoV-2 Variants of Concern/Interest.

  10. e

    Spike glycoprotein S2, coronavirus, heptad repeat 1

    • ebi.ac.uk
    Updated Oct 11, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2021). Spike glycoprotein S2, coronavirus, heptad repeat 1 [Dataset]. https://www.ebi.ac.uk/interpro/entry/InterPro/IPR044873
    Explore at:
    Dataset updated
    Oct 11, 2021
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    The type I glycoprotein S of Coronavirus, trimers of which constitute the typical viral spikes, is assembled into virions through noncovalent interactions with the M protein. The spike glycoprotein is translated as a large polypeptide that is subsequently cleaved to S1 ([interpro:IPR002551]) and S2 . The cleavage of S can occur at two distinct sites: S2 or S2' . The spike is present in two very different forms: pre-fusion (the form on mature virions) and post-fusion (the form after membrane fusion has been completed). The spike is cleaved sequentially by host proteases at two sites: first at the S1/S2 boundary (i.e. S1/S2 site) and second within S2 (i.e. S2' site). After the cleavages, S1 dissociates from S2, allowing S2 to transition to the post-fusion structure . Both chimeric S proteins appeared to cause cell fusion when expressed individually, suggesting that they were biologically fully active . The spike is a type I membrane glycoprotein that possesses a conserved transmembrane anchor and an unusual cysteine-rich (cys) domain that bridges the putative junction of the anchor and the cytoplasmic tail .SARS-CoV S is largely uncleaved after biosynthesis. It can be later processed by endosomal cathepsin L, trypsin, thermolysin, and elastase, which are shown to induce syncytia formation and virus entry. Other proteases that are of potential biological relevance in potentiating SARS-CoV S include TMPRSS2, TMPRSS11a, and HAT which are localized on the cell surface and are highly expressed in the human airway . The furin-like S2' cleavage site at KR/SF with P1 and P2 basic residues and a P2' hydrophobic Phe downstream of the IFP is identical between the SARS-CoV-2 and SARS-CoV. One or more furin-like enzymes would cleave the S2' site at KR/SF . Deletion of SARS-CoV-2 furin cleavage site suggests that it may not be required for viral entry but may affect replication kinetics and altered sites have been still seen proteolytically cleaved. Several substitutions within the S2' cleavage domain of SARS-COV-2 have been reported, including P812L/S/T, S813I/G, F817L, I818S/V, but further experimental study of their consequences and the replication properties of the altered viruses are required to understand the role of furin cleavage in SARS-CoV-2 infection and virulence .

  11. t

    GISAID Spike Covid Proteins

    • service.tib.eu
    Updated Dec 16, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2024). GISAID Spike Covid Proteins [Dataset]. https://service.tib.eu/ldmservice/dataset/gisaid-spike-covid-proteins
    Explore at:
    Dataset updated
    Dec 16, 2024
    Description

    The dataset of spike Covid proteins was obtained from GISAID. Each protein in the dataset is represented as a sequence of amino acids (AAs).

  12. I

    Data from: Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine...

    • data.niaid.nih.gov
    url
    Updated Mar 28, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2024). Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis [Dataset]. http://doi.org/10.21430/m3sjr04zkv
    Explore at:
    urlAvailable download formats
    Dataset updated
    Mar 28, 2024
    License

    https://www.immport.org/agreementhttps://www.immport.org/agreement

    Description

    Background: Cases of adolescents and young adults developing myocarditis after vaccination with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-targeted mRNA vaccines have been reported globally, but the underlying immunoprofiles of these individuals have not been described in detail. Methods: From January 2021 through February 2022, we prospectively collected blood from 16 patients who were hospitalized at Massachusetts General for Children or Boston Children's Hospital for myocarditis, presenting with chest pain with elevated cardiac troponin T after SARS-CoV-2 vaccination. We performed extensive antibody profiling, including tests for SARS-CoV-2-specific humoral responses and assessment for autoantibodies or antibodies against the human-relevant virome, SARS-CoV-2-specific T-cell analysis, and cytokine and SARS-CoV-2 antigen profiling. Results were compared with those from 45 healthy, asymptomatic, age-matched vaccinated control subjects. Results: Extensive antibody profiling and T-cell responses in the individuals who developed postvaccine myocarditis were essentially indistinguishable from those of vaccinated control subjects, despite a modest increase in cytokine production. A notable finding was that markedly elevated levels of full-length spike protein (33.9±22.4 pg/mL), unbound by antibodies, were detected in the plasma of individuals with postvaccine myocarditis, whereas no free spike was detected in asymptomatic vaccinated control subjects (unpaired t test; P<0.0001). Conclusions: Immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine-induced immune responses did not differ between individuals who developed myocarditis and individuals who did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post-mRNA vaccine myocarditis, advancing insight into its potential underlying cause.

  13. f

    Data from: Drug repurposing and sequence analysis in S-glycoprotein variants...

    • tandf.figshare.com
    txt
    Updated Aug 31, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Devang Haresh Liya; Nithishwer Mouroug Anand; Ashwin Kumar Jainarayanan; Mirudula Elanchezhian; Madhumati Seetharaman; Dhanuush Balakannan; Arpit Kumar Pradhan (2023). Drug repurposing and sequence analysis in S-glycoprotein variants reveals critical signature patterns and destabilization of receptor-binding domain in omicron variant [Dataset]. http://doi.org/10.6084/m9.figshare.21231754.v1
    Explore at:
    txtAvailable download formats
    Dataset updated
    Aug 31, 2023
    Dataset provided by
    Taylor & Francis
    Authors
    Devang Haresh Liya; Nithishwer Mouroug Anand; Ashwin Kumar Jainarayanan; Mirudula Elanchezhian; Madhumati Seetharaman; Dhanuush Balakannan; Arpit Kumar Pradhan
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    The evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus since its emergence in 2019 has yielded several new viral variants with varied infectivity, disease severity, and antigenicity. Although most mutations are expected to be relatively neutral, mutations at the Spike region of the genome have shown to have a major impact on the viral transmission and infection in humans. Therefore, it is crucial to survey the structures of spike protein across the global virus population to contextualize the rate of therapeutic success against these variants. In this study, high-frequency mutational variants from different geographic regions were pooled in order to study the structural evolution of the spike protein through drug docking and MD simulations. We investigated the mutational burden in the spike subregions and have observed that the different variants harbour unique signature patterns in the spike subregions, with certain domains being highly prone to mutations. Further, the MD simulations and docking study revealed that different variants show differential stability when docked for the same set of drug targets. This work sheds light on the mutational burden and the stability landscape of the spike protein across the variants from different geographical regions. Communicated by Ramaswamy H. Sarma

  14. m

    Unprocessed SARS-CoV-2 spike Nucleotide Sequences

    • data.mendeley.com
    Updated Mar 28, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Roberth Rojas Chavez (2024). Unprocessed SARS-CoV-2 spike Nucleotide Sequences [Dataset]. http://doi.org/10.17632/wn7jwk9n22.5
    Explore at:
    Dataset updated
    Mar 28, 2024
    Authors
    Roberth Rojas Chavez
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description
    1. Sequence GenBank IDs of all 615,374 nucleotide spike sequences isolated from samples collected between December 2019 and July 2021.
    2. Nucleotide alignment of the 16,808 unique spike sequences derived from the above.
    3. Baseline Sequence IDs collected up to July 2021
    4. B.1.1.7 Sequences IDs collected up to March 2022
    5. P.1 Sequences IDs collected up to February 2022
    6. AY.4 Sequences IDs collected up to February 2022
    7. AY.4.2 Sequences IDs collected up to February 2022
    8. BA.1 Sequences IDs collected up to February 2022
    9. BA.1.1 Sequences IDs collected up to March 2022
    10. BA.2 Sequences IDs collected up to March 2022
    11. Biosample accession of deep sequenced patient samples
    12. Newick tree for figure 1B - S3 Data
    13. Newick tree for figure 2A - S4 Data
    14. BA.4 Sequences IDs collected up to April 2023
    15. BA.5 Sequences IDs collected up to April 2023
  15. Cumulative cases of COVID-19 in the U.S. from Jan. 20, 2020 - Nov. 11, 2022,...

    • statista.com
    Updated Nov 17, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2022). Cumulative cases of COVID-19 in the U.S. from Jan. 20, 2020 - Nov. 11, 2022, by week [Dataset]. https://www.statista.com/statistics/1103185/cumulative-coronavirus-covid19-cases-number-us-by-day/
    Explore at:
    Dataset updated
    Nov 17, 2022
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    Jan 20, 2020 - Nov 11, 2022
    Area covered
    United States
    Description

    As of November 11, 2022, almost 96.8 million confirmed cases of COVID-19 had been reported by the World Health Organization (WHO) for the United States. The pandemic has impacted all 50 states, with vast numbers of cases recorded in California, Texas, and Florida.

    The coronavirus in the U.S. The coronavirus hit the United States in mid-March 2020, and cases started to soar at an alarming rate. The country has performed a high number of COVID-19 tests, which is a necessary step to manage the outbreak, but new coronavirus cases in the U.S. have spiked several times since the pandemic began, most notably at the end of 2022. However, restrictions in many states have been eased as new cases have declined.

    The origin of the coronavirus In December 2019, officials in Wuhan, China, were the first to report cases of pneumonia with an unknown cause. A new human coronavirus – SARS-CoV-2 – has since been discovered, and COVID-19 is the infectious disease it causes. All available evidence to date suggests that COVID-19 is a zoonotic disease, which means it can spread from animals to humans. The WHO says transmission is likely to have happened through an animal that is handled by humans. Researchers do not support the theory that the virus was developed in a laboratory.

  16. I

    Data from: Neutralizing antibody against SARS-CoV-2 spike in COVID-19...

    • immport.org
    • data.niaid.nih.gov
    url
    Updated Aug 25, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2023). Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors [Dataset]. http://doi.org/10.21430/M3BAM4CN94
    Explore at:
    urlAvailable download formats
    Dataset updated
    Aug 25, 2023
    License

    https://www.immport.org/agreementhttps://www.immport.org/agreement

    Description

    To describe a sensitive and reliable SARS-CoV-2 S�bearing lentivirus inGluc neutralization assay that is validated by the authentic SARS-CoV-2 plaque-reduction assay

  17. I

    Data from: Omicron variant Spike-specific antibody binding and Fc activity...

    • immport.org
    • data.niaid.nih.gov
    url
    Updated Sep 2, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2022). Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines [Dataset]. http://doi.org/10.21430/M3LUE504P0
    Explore at:
    urlAvailable download formats
    Dataset updated
    Sep 2, 2022
    License

    https://www.immport.org/agreementhttps://www.immport.org/agreement

    Description

    To examine the ability of vaccine-induced antibodies to drive Fc effector activity against Omicron variant using samples from individuals receiving BNT162b2, mRNA-1273 or CoronaVac vaccination

  18. d

    Data from: Characterization of the anti-spike IgG immune response to...

    • search.dataone.org
    • data.niaid.nih.gov
    • +1more
    Updated May 3, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Emily Ricotta (2024). Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies [Dataset]. http://doi.org/10.5061/dryad.6hdr7sr68
    Explore at:
    Dataset updated
    May 3, 2024
    Dataset provided by
    Dryad Digital Repository
    Authors
    Emily Ricotta
    Time period covered
    Jan 1, 2023
    Description

    Research on COVID-19 vaccination in immune-deficient/disordered people (IDP) has primarily focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers, anti-spike IgG was detected in 88% of IDP post-dose 2, increasing to 93% by six months post-dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed 1/3 that of healthy volunteers. IgG binding to Omicron BA.1 was lower than all other variants. Angiotensin-converting enzyme 2 pseudo-neutralization (% inhibition) was only modestly correlated with anti-spike IgG concentration. IgG levels were not significantly altered by participants’ use of different mRNA-based vaccines, immunomodulating treatments, and prior SARS-CoV-2 infections. While our data show that three doses of COVID-19 vaccinations induce anti-spike IgG in most IDP, additional doses are needed to achieve the levels of protection in healthy volunteers. Due to the strikingly reduced IgG response to Omi..., All methods for the collection and processing of these data are published in the associated manuscript. Code and survey instruments are available at https://doi.org/10.5281/zenodo.8428160., , # Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

    https://doi.org/10.5061/dryad.6hdr7sr68

    This data was collected as part of the PERSIST cohort study (NCT04852276), which aimed to assess the immune response to COVID-19 vaccines in people with immune disorders and healthy volunteers. We collected and analyzed data from April 2021 through April 2022 for this study. Laboratory methods that describe the assay specifics can be found in the associated publication, “Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies†in Science Advances.  Five unique datasets were used in our study. Four datasets were derived from participant data:

    1. “Final_ELISA_data_v2†provides ELISA measurements of the anti-spike IgG antibody concentration in response to vaccination in all our participants. The file ...
  19. z

    Simulation of Receptor Binding Domain of SARS-CoV-2 spike protein (WT and...

    • zenodo.org
    bin
    Updated May 18, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dhiman Ray; Dhiman Ray; Riley N. Quijano; Ioan Andricioaei; Riley N. Quijano; Ioan Andricioaei (2022). Simulation of Receptor Binding Domain of SARS-CoV-2 spike protein (WT and variants) in complex with neutralizing antibodies. [Dataset]. http://doi.org/10.5281/zenodo.6558396
    Explore at:
    binAvailable download formats
    Dataset updated
    May 18, 2022
    Dataset provided by
    Zenodo
    Authors
    Dhiman Ray; Dhiman Ray; Riley N. Quijano; Ioan Andricioaei; Riley N. Quijano; Ioan Andricioaei
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    This repository contains the molecular dynamics trajectories of the SARS-CoV-2 Spike RBD bound to BD23 and B38 monoclonal antibodies. The simulations for the RBD only systems are also provided. The trajectories are available for the WT spike protein as well as for four different variants (alpha, beta, kappa and delta). The simulations of the RBD only system are propagated for 300 ns and for the RBD-Antibody complex for 500 ns. The trajectories are saved at 100 ps interval. The Steered MD simulation trajectories (WT_RBD_B38_SMD_1.dcd etc.) and collective variables files are also included (WT_RBD_B38_SMD_1.colvars.traj etc.). There are 5 SMD trajectories for each RBD antibody pair. The details of the simulation can be obtained from the preprint: https://doi.org/10.1101/2021.08.13.456317

  20. Production and purification of receptor-binding domain (RBD) of the Spike...

    • zenodo.org
    Updated Nov 5, 2020
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Seitova A.; Seitova A. (2020). Production and purification of receptor-binding domain (RBD) of the Spike protein from a transiently transfected mammalian cell [Dataset]. http://doi.org/10.5281/zenodo.4091746
    Explore at:
    Dataset updated
    Nov 5, 2020
    Dataset provided by
    Zenodohttp://zenodo.org/
    Authors
    Seitova A.; Seitova A.
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Production and purification of recombinant receptor-binding domain (RBD) of the Spike protein from a transiently transfected EXPI293 mammalian cell .

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Executive Office of Health and Human Services (2022). COVID-19 reporting [Dataset]. https://www.mass.gov/info-details/covid-19-reporting

COVID-19 reporting

Explore at:
Dataset updated
Oct 21, 2022
Dataset provided by
Department of Public Health
Executive Office of Health and Human Services
Area covered
Massachusetts
Description

The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

Search
Clear search
Close search
Google apps
Main menu